Actualités sur Pharma

29.07.2004 – 14:09
Baxter International Inc.
Baxter and Cerus Enter Agreement with Asian Partner for Commercialization of Intercept Blood System for Platelets - Agreement to Help Address the Need for a Safer Blood Supply in Asia
DEERFIELD, Ill., and CONCORD, Calif. (ots) - Subsidiaries of Baxter International Inc. (NYSE: BAX) and Cerus Corporation (NASDAQ: CERS) today announced that they have entered into a definitive agreement with BioOne Corporation for commercialization of the INTERCEPT Blood System for platelets in parts of Asia. The ...
plus
19.07.2004 – 13:37
AOP Orphan Pharmaceuticals AG
AOP Orphan Pharmaceuticals AG obtains Thromboreductin® registrations in Central Europe
Vienna, Austria (ots) - AOP Orphan Pharmaceuticals, manufacturer and product developer of Thromboreductin®, announces that it has achieved its intermediate goal to make Thromboreductin® available in the European Union by means of an ambitious GCP compliant clinical trial programme. Thromboreductin is the first Anagrelide containing medicinal product approved ...
plus
01.03.2004 – 13:10
Novo Nordisk
Switzerland is first to launch new diabetes therapy - Levemir® (insulin detemir)
Geneva (ots) - Novo Nordisk Switzerland announced today that Levemir® (insulin detemir), a novel, predictable basal insulin analogue with a unique mechanism of prolonging action (scientifically known as protraction), is available for people with type 1 and type 2 diabetes in Switzerland today. The Swiss launch is just the beginning of an exciting global roll-out of ...
plus
19.11.2003 – 14:23
Amersham Biosciences
Amersham Biosciences Updates CodeLink Informatics Solution to Provide Complete Data Management
Piscataway, NJ (ots) - Amersham Biosciences, the life sciences business of Amersham (LSE:, NYSE:, OSE: AHM), has enhanced its CodeLink Informatics Solution to help scientists to improve productivity further by streamlining data extraction, acquisition and management processes in their gene expression experiments. The suite of tools includes CodeLink Expression ...
plus
17.11.2003 – 08:39
William Ransom & Son plc
Interim results for the six months to 30 September 2003 - Busines transformation process continues
London (ots) - William Ransom & Son plc, the natural healthcare company, announced today a pre-tax profit before amortisation of goodwill of £0.055m in its interim results to 30 September 2003 (pre-tax loss of £0.095m after amortisation of goodwill). The Directors have declared a dividend of 0.50p. In summary: · Turnover declined by 1.6% to £6.731 ...
plus
04.11.2003 – 12:22
Antisoma plc
Antisoma promotes Nick Adams to Director of Business Development
London, UK (ots) - Antisoma, (LSE: ASM) the biopharmaceutical company specialising in the development of novel anti-cancer drugs, today announces the promotion of Mr Nicholas Adams to Director of Business Development. Nick will lead Antisoma's business development team, for which a key focus remains the acquisition of new products to add to Antisoma's pipeline. He has also been appointed to Antisoma's Executive ...
plus

15.10.2003 – 15:52
William Ransom & Son plc
William Ransom & Son plc plans Site Sale: Reorganisation should yield cash and operational cost benefits
London (ots) - William Ransom, the natural healthcare company, today confirmed that it is considering the sale of its valuable Hitchin town centre site for residential development. A reorganisation would produce operational savings as pharmaceutical manufacture is transferred to the company's Witham site. Cash ...
plus
09.09.2003 – 08:38
Antisoma plc
Antisoma Acquires Cytogen's Royalty Rights To R1549
London, UK and Princeton, New Jersey USA (ots) - Antisoma plc (LSE: ASM; Nasdaq Europe: ASOM), a United Kingdom-based biopharmaceutical company, and Cytogen Corporation (Nasdaq: CYTO), a United States-based, product-driven, oncology-focused biopharmaceutical company, today announced that Antisoma has acquired certain royalty rights to Antisoma's lead product, R1549 (formerly Pemtumomab), from Cytogen. In connection ...
plus
26.08.2003 – 08:37
Antisoma plc
Antisoma to de-list from Nasdaq Europe because of forthcoming closure of market Shares to remain listed on the London Stock Exchange
London, UK (ots) - Antisoma (LSE: ASM- Nasdaq Europe: ASOM), the UK-based biopharmaceutical company, today announces that it has received approval for a voluntary de-listing from the Nasdaq Europe Market. The de-listing of Antisoma shares will be effective from the close of business on Wednesday 10 September ...
plus
31.07.2003 – 08:54
GfK Gruppe
The GfK Group expands its HealthCare activities in the USA / Acquisition of majority shareholding in US pharma market research specialists V2
Nuremberg, Germany (ots) - With effect from 31 July 2003, the GfK Group will acquire a stake of 51 per cent in pharma market research specialists V2 in Pennsylvania, USA. This acquisition grants GfK access to the most important market for information services relating to pharmaceuticals, biotechnology and medical ...
plus
11.06.2003 – 13:38
Novartis Ophthalmics
New Data From Visudyne® In Minimally Classic(VIM) Trial Confirm Importance Of Lesion Size In The Treatment Of "Wet" AMD
Madrid (ots) - New data from the VIM study presented today at the annual Congress of the European Society of Ophthalmology (SOE) demonstrate that Visudyne® therapy benefited patients with smaller base line lesions* in minimally classic "wet" AMD, a form of AMD previously considered untreatable.1 Visudyne is the ...
plus
16.12.2002 – 08:28
Bayer AG
Treatment of uncomplicated urinary tract infections / U.S. registration for Bayer's Cipro(R) XR antibiotic / Once-a-day dosing simplifies administration
Leverkusen (ots) - The U.S. Food and Drug Administration (FDA) has approved Bayer's antibiotic product Cipro(R) XR (Ciprofloxacin Extended-Release Tablets). This new formulation, given once a day over three days, is designed to treat uncomplicated urinary tract infections (UTIs). Cipro(R) XR will be marketed in a ...
plus

30.07.2002 – 10:47
Interpharma
Actelion joins Interpharma as associate member
Basel (ots) - Biopharmaceutical company Actelion has become the newest member of Interpharma, the Association of Pharmaceutical Research Companies of Switzerland. Headquartered in Allschwil, canton Baselland, Actelion was accepted as an associate member at Interpharma's most recent general assembly. Associate member status gives Actelion a seat on the expanded Executive Board and on all of the association's task ...
plus
18.04.2002 – 07:15
Novartis International AG
Novartis continues on dynamic growth path as Pharmaceuticals increases market share
Basel (ots) - * First-quarter Group sales up 13% in local currencies (10% in Swiss francs) * Pharmaceuticals extends double-digit sales growth (+16% in local currencies; +14% in Swiss francs), driven by strong demand for cardiovascular, oncology and ophthalmic products in all regions * Net profits surge ...
plus
09.01.2002 – 11:53
Biomit Inc.
Biomit Inc. Continues Expansion in Europe Affiliate office opened in Germany; representation in Benelux and Great Britain
Basel, Switzerland (ots) - Biomit Inc., a strategic e-clinical research partner for the biopharmaceutical industry, continues to establish offices throughout Europe as it expands its integrated worldwide representation. Today marks the official opening of its office in Heidelberg, which will coordinate on-line, ...
plus

Précédent3456789101112